$11.1 Million Placement Completed to Advance azer-cel
Filed with ASX · · 5 pages · English
Summary by 6ix AI
Imugene Ltd has announced the completion of a placement to raise funds for its lead asset, azer-cel, following positive clinical data from a recent trial cohort. The placement is expected to generate significant funding to support ongoing clinical and regulatory milestones for azer-cel, as well as general working capital. The company has received strong support from both new and existing institutional investors, including a global biopharmaceutical company. Recent clinical updates indicate promising early results for azer-cel in treating specific blood cancers, enhancing its potential market value.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Story so far
Earlier from Imugene
- New Complete Response in the Concurrent BTKi azer-cel Cohort
- First Complete Response in Concurrent BTKi azer-cel Cohort
- Azer-cel Granted FDA Fast Track Designation for CLL and MZL
- First Patient in BTKi Combination Cohort of azer-cel study
- Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract
Later from Imugene
- Third response in concurrent BTKi Cohort of azer-cel Trial
- azer-cel BTKi Cohort Reports new Complete & Partial Response
- Further Responses in azer-cel Phase 1b Trial
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene